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Abstract
The gastrointestinal epithelium does much more than provide a physical barrier between the intestinal
lumen and our internal milieu. It is actively engaged in absorption and secretion of salt and water via
ion transporters, exchangers and selective ion channels. It is also a continuously self-renewing
epithelium that undergoes ordered growth and differentiation along its vertical axis. From this dual
perspective, we will consider the actions of the ERBB family of ligands and receptors in the
maintenance of gastrointestinal homeostasis and discuss instances when the actions of this family
go awry such as in cancer and Ménétrier's disease.
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Introduction
This review is intended to highlight recent important advances in our understanding of roles
for ERBBs in gastrointestinal biology and pathology. We published a similar review in
Gastroenterology in 1995 [1], and it is gratifying to note the progress that has been made in
this field since that time. More recently, we provided an update on EGF receptor (EGFR)
ligands in this journal [2]. Due to space constraints, this review perforce is highly selective,
and we apologize in advance to our colleagues for omissions of relevant published work. The
focus will be on selected topics where substantial progress has been made, e.g., transactivation
of the EGFR, interactions between microbes in the gut and EGFR and insights into
gastrointestinal homeostasis based on relevant genetic manipulations in the mouse. We also
will point out gaps in our knowledge and emerging areas of opportunity. This review is not
intended to be comprehensive. For example, the liver and pancreas are not discussed, although
the interested reader is referred to several reviews related to the pancreas [3,4].
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The four members of the ERBB family are depicted in Fig. 1. In contrast to the other family
members, ErbB3 lacks intrinsic tyrosine kinase activity but contains 6 PI3-K binding sites
within its cytoplasmic tail. Family members can homo- and heterodimerize. Preformed dimers
may exist [5], but ligand binding results in oligomerization of the receptors, activation of
intrinsic tyrosine kinase activity and transphosphorylation of tyrosine residues on the partnered
receptor that initiates a complex signal transduction cascade. ErbB2 lacks a ligand but is
thought to be the preferred binding partner of the other ErbBs [6,7]. All seven of the vertebrate
EGFR ligands are synthesized as type-1 transmembrane proteins (Fig. 1). Upon insertion into
the plasma membrane, they undergo ectodomain cleavage by cell surface proteases to release
soluble ligand that then engages the receptor. In some cases, membrane-bound ligand is not
cleaved, and can signal through adjacent receptor-bearing cells (juxtacrine signaling), a process
best documented for HB-EGF [8–10]. Considerably more detail on these topics is presented
elsewhere in this monograph.
In the normal adult human gut and in a battery of polarizing human colorectal cancer (CRC)
cell lines, EGFR is found predominantly at the basolateral surface [11], as presumably are
ErbB2–4 [12]. The pathophysiological significance of apical EGFRs, if any, is less certain
[13]. At sites of acute and chronic injury, basolateral EGFRs become exposed to the luminal
environment and may be accessed by endogenous luminal EGFR ligands such as EGF or the
administration of EGF enemas [14]. Playford and Wright introduced the apt term “luminal
surveillance peptide” to describe the action of EGF that is secreted into the gut lumen by the
salivary gland and Brunner's glands [15]. A similar phenomenon was described by Welsh et
al. for apically released heregulin accessing basolateral ErbB3 and 4 in the damaged lung
[16]. All components of the EGFR axis (defined as the proximal events in activation of EGFR)
are found at the basolateral compartment of two human polarizing CRC cell lines (HCA-7 and
Caco-2) derived from well-differentiated CRCs [17]. That is, TGFα and amphiregulin are
delivered selectively to the basolateral surface where they are cleaved by TNF-α converting
enzyme (TACE)/a disintegrin and metalloprotease (ADAM)-17 to release mature soluble
ligand that then binds basolaterally restricted EGFRs.
TGFα is touted to be the most abundant EGFR ligand in the GI tract [18]. David Lee et al.
assessed mRNA expression of all of the EGFR ligands (except epigen) from the stomach to
the colon in the mouse [19]. Less is known about the precise localization of the ErbB family
and its ligands along the vertical axis of the gut. Our impression is that in the normal colon
there is a decreasing gradient of expression for TGFα and EGFR from the luminal surface to
the crypt base with a sharper gradient for TGFα than EGFR. However, following fasting and
refeeding in the rat, TGFα immunoreactivity extends towards the crypt base in the colon (RJ
Coffey, unpublished observation). Bertagnoli et al. have observed a similar gradient of EGFR
immunoreactivity from the villous tip to the crypt base in the mouse small intestine [20].
A systematic analysis at the protein level of the ERBB family and its cognate ligands along
the horizontal and vertical gradient of the gastrointestinal tract has not been performed. Such
an analysis should assess total and phosphorylated ERBBs; ideally, this would delineate
phosphorylation status of specific tyrosine residues. This may be particularly relevant in the
neoplastic state since we have observed that Ras transformation of RIE-1 cells in vitro results
in downregulated, yet tyrosine hyperphosphorylated, EGFR [21]. Such a systematic analysis
of receptors and ligands has, thus far, been limited due to technical difficulties. Western blotting
requires adequate amounts of tissue, and immunohistochemistry is fraught with issues related
to specificity, quantification, preservation of antigenicity and fixation artifacts. Application of
advances in mass spectrometry may be a useful direction to pursue in this area, especially in
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the assessment of the phosphorylation state of specific tyrosine residues in the cytoplasmic
tails of the different ERBBs.
Transactivation of the EGFR
Transactivation of the EGFR was defined operationally by Ullrich et al. as G Protein-Coupled
Receptor (GPCR)-triggered signaling (specifically MAP kinase and SHC phosphorylation)
that was blocked by EGFR tyrosine kinase inhibition. As described below, it initially was
thought to be ligand-independent; however, it subsequently was shown to be due to
metalloproteinase-regulated cell surface cleavage and release of mature soluble EGFR ligand.
Ligand engagement of EGFR activated its intrinsic tyrosine kinase and initiated downstream
signaling. Instances of GPCR-triggered, EGFR ligand-independent EGFR activation have been
reported, but their mechanistic underpinnings are less clear. Furthermore, one can envision
GPCR-mediated EGFR signaling that may not depend upon EGFR tyrosine kinase activation.
For example, GPCR activation of Src tyrosine kinase activity may lead to direct
phosphorylation of tyrosine (Y)845 within the EGFR cytoplasmic tail [22]. In this case, EGFR
may act as a docking site for SH2-containing proteins and subsequent signal transduction. To
further complicate matters, active Src may also activate TACE/ADAM17 and lead to ligand-
dependent EGFR activation [23]. Finally, it should be recalled that there can be GPCR-
independent, ligand-dependent transactivation of the EGFR. One example is the phorbol ester
TPA, presumably acting as a general cell surface sheddase [24]. However, this action of TPA
may be counter-balanced by a PKC-mediated phosphorylation of threonine (T)654 within the
cytoplasmic tail of the EGFR that results in receptor internalization and downregulation.
What follows is a brief historical review of GPCR transactivation of the EGFR. In 1996, Ullrich
et al. first reported that the GPCR agonists endothelin-1 (ET-1), lysophosphatidic acid (LPA)
and thrombin induced tyrosine phosphorylation of EGFR (and ErbB2/c-neu) within 2 min of
their administration to Rat-1 fibroblasts [25]. Given the rapid kinetics of this effect, they
concluded that EGFR activation must be ligand-independent; however, they were not able to
formally exclude this possibility because monoclonal antibodies (mAbs) to block ligand
binding to rat EGFR were not available at that time. They postulated that the effect was due to
an intracellular release of a negative restraint (likely a phosphatase) on receptor tyrosine kinase
activity.
In collaboration with Steve Wiley, we published in early 1999 that a broad spectrum,
hydoxymate-based, metalloproteinase inhibitor, batimastat, could reduce the growth of HCA-7
cells and, importantly, that addition of EGF reversed the growth inhibitory effect of batimastat
[26]. Similar results were observed in a human mammary epithelial cell line (HMEC);
moreover, in, these cells, the metalloproteinase inhibitor reduced the levels of TGFα and AR
in the medium, and a combination of batimastat and an EGFR mAb that blocked ligand binding
resulted in cooperative growth inhibition of these cells. This work identified a
metalloproteinase-regulated EGFR activity that was mediated by endogenous EGFR ligands.
Later in 1999, Ulrich et al. revisited their initial contention that GPCR transactivation of the
EGFR was ligand-independent [27]. Using Rat-1 cells expressing a chimeric human EGFR
ectodomain fused to PDGFR transmembrane and cytoplasmic tail, they demonstrated that
EGFR transactivation was prevented by a mAb that blocked ligand binding to human EGFR.
They implicated HB-EGF as the EGFR ligand mediating this transactivation by exploiting the
observation that HB-EGF acts as a receptor for diphtheria toxin. CRM197 (a non-toxic mutant
of diphtheria toxin that specifically inhibits the mitogenic effects of cells producing HB-EGF)
was able to block EGFR transactivation by GPCR agonists in COS-7 and HEK 293 cells;
however, CRM197 did not affect exogenous EGF-induced EGFR tyrosine phosphorylation.
Likewise, batimastat was able to abrogate GPCR agonist and TPA transactivation of the EGFR
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in COS-7 cells. Finally, batimastat was shown to prevent bombesin (another GPCR agonist)
and TPA-induced tyrosine phosphorylation of EGFR in a prostate cancer cell line, PC3.
Consistent with our earlier work [26], batimastat was able to reduce baseline tyrosine
phosphorylation of EGFR in these cells.
These studies established that GPCR transactivation of EGFR was rapid and EGFR ligand-
dependent but did not identify the specific metalloproteinase. By noting that TPA-, but not
GPCR-induced tyrosine phosphorylation of EGFR, was sensitive to protein kinase C inhibition,
they suggested that at least two distinct metalloproteinase-dependent transactivation pathways
existed. As noted above, work from our lab has shown that TACE/ADAM-17 localizes to the
basolateral surface of polarized HCA-7 cells and that a selective TACE/ADAM-17 inhibitor
WAY022 blocks cell surface release of AR and TGFα in these cells [17].
These original observations have spawned a small cottage industry related to GPCR
transactivation of EGFR in general [28] and in the gastrointestinal tract in particular (see Table
1). The role of EGFR transactivation in chloride secretion will be discussed in more detail as
it illustrates several points we wish to highlight (Fig. 2). Barrett et al. identified one of the first
examples of GPCR transactivation of EGFR in the gut. Using a polarizing human colorectal
cancer cell line (T84), they showed that the muscarinic (M) agonist carbachol (CCh), a stable
analogue of the neurotransmitter acetylcholine, transactivates EGFR in a TGFα-dependent
manner [29]. By binding to the basolateral M3 receptor (a GPCR), CCh stimulates apical
chloride secretion by a mechanism that requires increases in intracellular calcium (left panel
in Fig. 2A). The active secretion of chloride ions provides the driving force for intestinal fluid
secretion. Binding of CCh to the M3 receptor also results in a rapid metalloproteinase-
dependent release of TGFα into the basolateral medium and avid consumption by basolateral
EGFRs (right panel in Fig. 2A), activation of EGFR and transmission of an ERK-mediated
signal that blunts apical chloride secretion. The CCh-mediated transactivation of EGFR and
subsequent suppression of chloride secretion does not appear to involve PI3-K, unless PTP1B,
which dephosphorylates a number of EGFR tyrosine residues, is suppressed [30].
Interestingly, administration of EGF and TGFα to the basolateral compartment also blunted
chloride secretion but through ERK and PI3-K signaling and, in the latter instance, this may
involve protein tyrosine phosphatases, including PTP1B [30]. The authors suggested that
exogenous EGF and TGFα may alter the activity of phosphatases that then dephosphorylate
certain key EGFR residues differently than CCh-regulated, TGFα-mediated EGFR
transactivation. In these experiments, exogenous EGF was more potent than TGFα and elicited
EGFR–ErbB2 heterodimerization that was not seen with equivalent concentrations of TGFα.
This work demonstrates a growth-independent effect of endogenous TGFα and supports our
original contention that TGFα acts locally [31]. In contrast, activation of PAR-2 results in
increased cAMP and ligand-independent transactivation of EGFR that stimulates CFTR-
mediated chloride secretion (Fig. 2B) [32]. In normal mouse colon, EGF inhibits cAMP-
dependent ion transport [33], but, in the background of inflammation, exogenous EGF also
stimulates sodium absorption (Fig. 2C) [34]. These studies emphasize the potential of EGFR
phosphorylation and dephosphorylation mechanisms to regulate recruitment of alternate
downstream signaling pathways following EGFR activation by different stimuli.
Based on these observations, it is tempting to speculate on potential mechanism(s) underlying
the diarrhea that is seen in 25% of patients receiving the EGFR neutralizing mAb cetuximab.
One could envision that EGFR blockade impairs the dampening of CCh-induced chloride
secretion but also abrogates the sodium absorption that takes place in the setting of ongoing
inflammation, a state that is increasingly linked to neoplasia. Obviously, one must also consider
the effects of EGFR blockade on growth and repair processes that may also contribute to the
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diarrhea associated with pharmacological blockade of the EGFR, as well as its effects on
microbes in the gut (see next section).
A question that arises is how many other signaling pathways act through EGFR. Recent studies
by Steve Wiley et al. in human mammary epithelial cells (HMEC) have found that EGFR is a
central coordinator of many disparate signaling inputs. In addition to activating GPCRs (LPA
receptors, calcium-sensing receptors, purinergic receptors), administration of VEGF, GH,
TNFα and IGF results in EGFR activation [35]. Moreover, ERK phosphorylation in response
to general stressors (sorbitol and anisomycin) was dependent on EGFR kinase activity.
However, not all roads converge upon EGFR since ERK phosphorylation following HGF
activation of Met was not dependent on EGFR signaling. On the other hand, in two colon cancer
cell lines (LoVo and Caco-2), Tarnawski et al. reported that PGE2-induced c-Met
phosphorylation was dependent upon EGFR activation [36]. These differing results may reflect
the contextual nature of signaling responses.
We wish to make several final points. An emerging theme is the convergence of signaling
pathways at the level of EGFR, and that the EGFR axis acts as a central hub in integrating
many, but certainly not all, cell surface signaling events. One interesting example is the
feedforward action of EGFR activation and its upregulation of COX-2. Amphiregulin
upregulates COX-2 expression. The COX-2 product, PGE2, induces expression of
amphiregulin that binds and activates EGFR that, in turn, further upregulates COX-2 [37]. It
is important to note that GPCRs can signal independently of EGFR [38]. GPCR transactivation
of EGFR has been documented in vivo [39]; however, it is only 10% as potent as exogenous
EGF in activating EGFR. Deconstructing the contribution of EGFR activation to GPCR
signaling will be complicated by identifying whether the effect is ligand-dependent or -
independent and, if it is ligand-dependent, which ligand and which metalloproteinase cleaves
that ligand. Such an analysis may be further complicated by the phenomenon of auto- and
cross-induction [40,41], as well as the recent identification of a tyrosine kinase-independent
action of EGFR [42]. Finally, one must also consider how GPCR transactivation of EGFR is
terminated. Recent studies have identified PKCα-mediated feedback inhibition as one such
mechanism [43–45].
Gut microbes and EGFR
Although EGFR and other ErbB receptors are involved in normal gastrointestinal development
and homeostasis (discussed below), they are also utilized by various infectious agents in
causing human disease. EGFR is employed by bacteria and viruses as a means of facilitating
invasion or cell entry, promoting cell survival early in the infectious process and also may play
a role in neoplastic progression that is associated with certain infections, such as
Helicobacter (H.) pylori. This section will review some of the ways in which microorganisms
interact with the ERBB system within the gut.
Enteropathogenic Escherichia coli (EPEC) is a diarrhea-causing pathogen that is responsible
for significant morbidity and mortality worldwide. Evidence suggests that EGFR signaling
may play a role in E. coli disease pathogenesis [46–48]. Such a link was suggested initially
when it was observed that oral administration of EGF to New Zealand white rabbits prevented
E. coli colonization of the small and large intestine and prevented diarrhea and weight loss in
the rabbits [47]. This observation may also have relevance to cetuximab-associated diarrhea.
Rather than being due to altered Cch-mediated chloride secretion, EGFR blockade may
facilitate pathogen-induced diarrhea. Additionally, internalization of EPEC into human renal
epithelial cells was inhibited by administration of the EGFR tyrosine kinase inhibitor AG1478
[48].
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In C2BBE intestinal epithelial cells infected with EPEC, there was a progressive increase in
phosphorylation of EGFR Y1068. Furthermore, C2BBE monolayers treated with filter-
sterilized supernatants of wild-type EPEC also stimulated Y1068 phosphorylation (although
it was comparatively less than when EPEC was present), suggesting that a secreted element
may be acting to induce this phosphorylation event. EGFR tyrosine phosphorylation was
inhibited by administration of AG1478, and this also attenuated EPEC-induced Akt and
ERK1/2 phosphorylation. When EGFR was inhibited by AG1478 in the setting of EPEC
infection, cell survival was decreased and IL-8 production was inhibited. These findings
suggest that EPEC can utilize the EGFR to promote host cell survival and increase IL-8
production [46].Itis possible that apoptosis of host cells early in bacterial infection is
detrimental to the pathogen, and that promoting host cell survival is important in disease
pathogenesis. Pseudomonas aeruginosa has also been shown to activate EGFR and
downstream ERK and PI3-kinase activity in a similar manner [49].
Clostridium difficile (C. diff) acts through a similar pathway. C. diff secretes two major toxins,
toxin A and toxin B, which are both high molecular weight exotoxins and are responsible for
the watery diarrhea characteristic of C. diff infection. Toxin B induces EGFR-mediated
activation of ERK1/2 phosphorylation, leading to release of IL-8 from human colon cell lines,
NCM460 and HT-29. Inhibition with AG1478 or EGFR neutralizing mAb blocks EGFR and
ERK activation, along with release of IL-8. TGFα was implicated as the ligand responsible for
activating EGFR in this system [50].
EGFR appears to be important in the invasion of another bacterial pathogen, Salmonella
typhimurium. In vitro exposure of S. typhimurium to two human intestinal epithelial cell lines,
Henle-407 and T84, induces EGFR tyrosine phosphorylation [33,51]. A strain of S.
typhimurium which is non-invasive due to a mutation in the invA gene does not induce this
phosphorylation. Addition of EGF to cultured Henle-407 cells allowed internalization of the
invasion-defective strain of S. typhimurium with mutant invA. However, addition of EGF did
not cause internalization of adherent, but non-invasive, Eschirichia coli [51]. These data
indicate that S. typhimurium can induce EGFR tyrosine phosphorylation which may contribute
to its internalization and invasive phenotype. In contrast, McNeil et al. studied S. typhimurium
in vitro and in vivo using Egfr (waved-2 [wa2]) mice that have a spontaneous mutation in the
EGFR tyrosine kinase domain resulting in markedly reduced (approximately 90%), but not
absent, intrinsic EGFR tyrosine kinase activity. S. typhimurium invaded fibroblasts from
wa2 mice as efficiently as fibroblasts from control animals. Moreover, in vivo, S.
typhimurium both invaded the gastrointestinal mucosa and penetrated through to the spleen in
wa2 mice [52]. Taken together, these data indicate that S. typhimurium has the ability to interact
with EGFR and induce phosphorylation, but this does not appear to be a necessary step in
invasion. Alternatively, the modest residual EGFR tyrosine kinase activity in wa2 mice may
be sufficient to mediate this effect.
Similarly, there is conflicting data on the importance of EGFR on the entry of human
cytomegalovirus (CMV) into epithelial cells. In 2003, Wang et al. proposed that EGFR was a
receptor responsible for cell entry of the virus [53]. CMV can activate both MAP-kinase [54,
55] and PI3-kinase [56], but a receptor for cell entry and signaling was not identified at the
time. Wang confirmed that CMV interacted with EGFR and activated downstream targets of
EGFR signaling such as PI3-kinase and Akt. This effect was inhibited by administration of
AG1478. Transfecting EGFR-negative MDA-MB453 cells with EGFR cDNA rendered non-
susceptible cells susceptible to CMV cell entry. CMV interacted with EGFR through
glycoprotein B, its principal surface envelope protein, and glycoproteinB promoted the hetero-
oligomerization of EGFR with ErbB3 [53]. On the other hand, Isaacson et al. found no
correlation between EGFR expression and CMV cell entry in a variety of cell lines (NHDF
and HEL fibroblasts, ARPE-19 retinal epithelial cells, UtMVEC and HUVEC endothelial cells)
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nor did EGFR neutralizing mAb block CMV entry into these cell lines [57]. Again, this may
indicate that CMV has the capacity in some cases to utilize the EGFR for cell entry and
signaling, but that is not necessarily an obligatory step.
In contrast to the above pathogens which cause acute illness, H. pylori is an organism that
colonizes the stomach during childhood and can lead to lifelong infection in the host if untreated
[58]. Approximately half of the world's population is infected with H. pylori, and it is known
to be associated with diseases such as atrophic gastritis, peptic ulcer disease [59–61],
lymphoma of mucosa-associated lymphoid tissue (MALT) and gastric adenocarcinoma [62,
63]. Among the responses of gastric epithelial cells to infection with H. pylori is increased
expression of EGFR [64], increased expression of EGFR ligands amphiregulin and HB-EGF
[65,66] and activation of EGFR signaling [67] which leads to upregulation of COX-2 and
VEGF in gastric epithelial cells [68].
Busiello et al. studied the virulence factors associated with changes in EGF-related peptides
and EGFR in two human gastric cancer cell lines, MKN28 and AGS [69]. They found that the
soluble protein gamma-glutamyltranspeptidase (GGT), a virulence and colonizing factor for
H. pylori, retained the ability to upregulate HB-EGF mRNA and protein expression after
fractionation from medium of cultured H. pylori strains. Acivicin, a selective GGT inhibitor,
counteracted the upregulation of HB-EGF by H. pylori, and upregulation of HB-EGF was not
observed following infection of gastric epithelial cells with an isogenic mutant GGT-deficient
strain of H. pylori. This effect appeared to be mediated through PI3-kinase and p38 kinase, as
their blockade with LY294002 or SB203580, respectively, inhibited H. pylori-induced
upregulation of HB-EGF, whereas blockade of MAP kinase with PD98059 had no such effect
[69].
In contrast to the above observations showing increased EGFR activity related to H. pylori
infection, Schiemann et al. observed that infection with H. pylori was associated with reduced
mRNA expression of TGFα, amphiregulin and HB-EGF [70]. Chronic gastritis due to H.
pylori was associated with decreased antral EGFR binding compared to healthy controls, as
assessed by [125I]-EGF binding. Moreover, in 19 patients with chronic H. pylori infection,
levels of these ligands increased after eradication therapy. The authors hypothesized that
reduced EGFR-mediated gastroprotection may contribute to the pathogenicity of H. pylori
infection [70].
These findings highlight the controversy surrounding the impact of H. pylori on EGF-related
peptide expression in human gastric mucosa. Other groups have found that HB-EGF and
amphiregulin are upregulated in the gastric mucosa of individuals infected with H. pylori
[71,72], and that this overexpression correlates with an increase in the mitotic index of the
gastric mucosa, as assessed by PCNA immunostaining [72]. However, Persico et al. noted
decreased expression of TGFα in the gastroduodenal mucosa of individuals infected with H.
pylori, similar to the observation of Schiemann et al. [73]. In light of these findings, it is clear
that more research is needed to further elucidate the interaction between H. pylori, EGF-related
peptides and EGFR signaling.
The cytotoxin-associated gene A product (CagA) is another H. pylori virulence factor that is
associated with higher grades of gastric inflammation and an increased risk of gastric cancer
[74]. Increased expression of EGFR is induced by H. pylori infection at both the mRNA and
protein level. This effect is limited to CagA+ strains of H. pylori and those with an intact type
IV secretion system [64]. Upregulation of HB-EGF is also more strongly induced by CagA+
strains of H. pylori than by CagA− strains [67]. It is unknown whether these findings contribute
to the increased oncogenic potential of CagA+ strains of H. pylori.
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Finally, it is useful to recall that HB-EGF serves as the receptor for the B fragment of Diphtheria
toxin [75].
Homeostasis
In this section, we will review the gastrointestinal consequences of genetic engineering of the
ERBB family and its ligands in the gut. The cumulative evidence suggests that EGFR signaling
contributes to mucosal integrity in response to damage and other provocative maneuvers.
Targeted disruption of the Egfr in mice results in strain-dependent effects. Using different
inbred strains, Threadgill et al. observed implantation lethality in CF-1 mice, midgestation
lethality in 129/Sv mice and perinatal lethality in CD-1 mice with these mice living past
weaning, at which time the overall gut architecture appeared normal [76]. However, Miettinen
et al. found that Egfr null mice on a mixed background exhibited features of necrotizing
enterocolitis (NEC) [77]. Moreover, a body of literature supports that EGFR ligands may
prevent NEC [78]. However, these ameliorative effects of EGFR ligands do not prove that loss
of Egfr in mouse gut directly causes NEC. It may be that that the NEC phenotype was secondary
to multi-organ failure and the overall debilitated state of these mice, or, alternatively, to
impaired barrier function and repair capability leading to enteropathogen susceptibility as
described above. Experiments comparing Egfr mutant mice in conditions with known bacterial
compositions will be required to elucidate whether NEC is a direct or indirect consequence of
Egfr deficiency. Nonetheless, more recent genetic data using conditional ablation of Egfr in
the gut epithelium using an Egfr conditional allele with the Villin-Cre transgene suggests that
NEC and other homeostatic defects are secondary to loss of Egfr which creates a sensitized
background [79].
Hypomorphic, homozygous wa2 mice have increased susceptibility to DSS-induced colitis
[80], as do TGFα null and epiregulin null mice [81,82]. Conversely, TGFα transgenic mice
exhibit decreased injury in response to DSS [83]. The lack of susceptibility to DSS-induced
colitis in the EGF, TGFα and AR triple null mice is likely due to differences in strain
backgrounds or health status of the respective colonies [19]. These triple null mice, however,
do exhibit spontaneous erosions in the duodenum.
Wa2 mice have reduced intestinal adaptation following 50% small bowel resection [84,85].
Mice overexpressing an assembled mouse EGF cDNA downstream of a rat intestinal fatty acid
binding promoter have 2-fold increased levels of EGF protein in the gut and exhibit enhanced
intestinal adaptation following small bowel resection [86]. Intestinal adaptation is not affected
in TGFα null mice [87], a finding that likely reflects ligand redundancy under these
experimental conditions.
The function of ErbB2 and ErbB4 in gastrointestinal homeostasis has not been evaluated
because embryos deficient for either die prenatally due to developmental defects of the heart
[88,89]. However, a conditional allele for ErbB3, which also leads to prenatal lethality when
deficient, has allowed its role to be evaluated. Mice lacking ErbB3 in the intestinal epithelium,
created by combining an ErbB3 conditional allele with the Villin-Cre transgene, develop
normally but show a high frequency of bifurcated villi [90]. The developmental cause of this
morphological change is not known but the mutant mice appear to have normal absorption
based upon body weight. Mice deficient for ErbB3 in the intestinal epithelium show elevated
susceptibility to DSS-induced colitis.
Esophagus
Increased EGFR signaling appears to play a role in the pathogenesis of both squamous cell
carcinoma (SCC) and adenocarcinoma of the esophagus. Increased EGFR expression is
common in SCC of the esophagus and has been associated with poor outcomes [91,92].A
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retrospective review of 107 cases of squamous cell carcinoma of the esophagus demonstrated
that 68.2% of cancers had overexpression of EGFR by immunohistochemistry [91]. Increased
expression was associated with a higher incidence of vascular invasion, higher local recurrence
rates and lower overall survival. Increased EGFR expression has also been associated with
higher rates of local spread to regional lymph nodes [92]. Although the majority of SCCs show
overexpression of EGFR by immunohistochemistry, only 21% of primary tumors exhibit DNA
amplification of EGFR by Southern blot analysis [93].
Rustgi et al. evaluated the effects of EGFR overexpression by retroviral transduction in normal
human epithelial cell lines EPC1 and EPC2. Compared with normal and GFP-transduced
primary human epithelial esophageal cells, cell cultures overexpressing EGFR demonstrated
a thicker epithelium and basal cell hyperplasia, as well as increased cell migration. These effects
were markedly diminished by addition of the EGFR tyrosine kinase inhibitor AG1478 to the
medium of these organotypic cultures. The effect of EGFR on cell migration appeared to be
dependent upon EGFR-induced upregulation of matrix metalloproteinase-1 (MMP-1) [94], an
effect which was mediated by the JAK-STAT pathway [95]. In vivo, a transgenic mouse model
of EGFR overexpression in the oral and esophageal squamous epithelia was also studied.
Compared with age-matched littermates, transgenic mice overexpressing EGFR in the
esophageal mucosa demonstrated increased proliferation in the basal and suprabasal cells,
consistent with the findings noted in cell culture [94].
More recently, the same group has used human epithelial cells as a platform to recapitulate
esophageal squamous cell cancer. This was accomplished by retroviral-mediated transduction
of EGFR, the catalytic subunit of human telomerase (hTERT) and p53R175H into normal human
esophageal epithelial cells. These transduced cells demonstrated increased migration and
invasion, and, in an organotypic 3-dimensional culture system, they formed a high grade
dysplastic epithelium with malignant cells invading the stromal extracellular matrix. The
invasive phenotype was mediated, in part, by matrix metalloproteinase-9 (MMP-9), and
invasion was attenuated by knockdown of both AKT1 and AKT2 [96].
EGFR also appears to play a role in Barrett's-associated adenocarcinoma of the esophagus.
Wang et al. showed that EGFR was expressed in 32% of adenocarcinomas of the esophagus,
and that expression of EGFR was associated with higher T stage, the presence of lymph node
metastases and also with a trend toward shorter disease-free survival in multivariate analysis
[97]. In addition to increased EGFR immunoreactivity, mutations in EGFR have been detected
in 11.7% of esophageal adenocarcinomas and 14.2% of cases of Barrett's esophagus [98]. In
this study, mutations consisted of the missense L858R mutation and in-frame deletion
delE746–A750. Both of these mutations are located in the tyrosine kinase domain of the
receptor and previously have been characterized as activating EGFR mutations in non-small
cell lung cancer which predict responsiveness to EGFR tyrosine kinase inhibitors [99–102].
The fact that these mutations are present in Barrett's esophagus, as well as adenocarcinoma,
suggests that there is a subset of adenocarcinomas of the esophagus in which mutation of EGFR
may play an early role in tumorigenesis [98]. TGFα and EGF appear to be involved in mucosal
defense in chronic reflux esophagitis [103,104], which is known to be associated with
development of esophageal adenocarcinoma [105]. This provides a plausible mechanism
through which chronic reflux could promote the neoplastic process in part by stimulating EGFR
signaling.
The role of ErbB2, ErbB3 and ErbB4 are less well defined in the pathogenesis of esophageal
carcinoma. The ErbB2 gene is amplified in approximately 21–32% of esophageal
adenocarcinomas arising out of Barrett's esophagus and 5–27% of Barrett's specimens with
high grade dysplasia [106,107]. Overexpression of ErbB2 by FISH was observed in 19% of
esophageal adenocarcinomas and correlated with poor prognosis [108]. No Barrett's samples
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with low grade dysplasia or intestinal metaplasia without dysplasia demonstrated increased
copy number of ErbB2 by quantitative RT-PCR [107]. This indicates that overexpression of
ErbB2 is involved in a subset of esophageal adenocarcinomas, although it is a relatively late
step in the metaplasia–dysplasia–carcinoma sequence. One uncontrolled Phase I/II study
evaluated the use of trastuzumab, a humanized monoclonal antibody that acts on the ErbB2
receptor, in patients with locally advanced esophageal adenocarcinomas that overexpressed
ErbB2 by immunohistochemistry. Nineteen patients were enrolled, and median survival was
24 months with a 2-year survival of 50% [109], numbers that are comparable with historical
controls. Due to the small proportion of adenocarcinomas that overexpress ErbB2, accrual for
this study was slow, and it was felt that an adequately powered Phase III study would be difficult
to perform.
ErbB3 has also been shown to be upregulated in esophageal adenocarcinoma through a
proteomic approach using high-resolution, two-dimensional gel electrophoresis and matrix-
assisted laser desorption/ionization, time-of-flight and tandem mass spectrometry analysis
(MALDI TOF MS) [110]. This finding was then validated using qRT-PCR and
immunohistochemical analysis on a tissue array. Fifty-one percent of tumors had increased
ErbB3 mRNA expression, and 42% had increased immunohistochemical staining for ErbB3
[110]. mRNA expression for ErbB4 and heregulin has been detected in esophageal mucosa
[111], but there is no clear evidence that alterations in their expression play a role in esophageal
carcinogenesis.
Stomach
In the stomach, enhanced EGFR signaling has been implicated in the pathogenesis of
Ménétrier's disease (hypoproteinemic hypertrophic gastropathy). In adults, this is a rare,
acquired, progressive overgrowth state of the stomach characterized by enlarged gastric folds
in the body and fundus of the stomach, hypochlorhydria and protein loss across the gastric
mucosa. Characteristic histological findings include foveolar hyperplasia with an expansion
of surface mucous cells at the expense of acid-producing parietal cells and pepsinogen-
producing chief cells [112]. The condition appears to be associated with an increased risk of
malignancy, although the magnitude of this risk is not known [113–118].
Evidence from mice and humans supports a role for excess EGFR signaling in the pathogenesis
of Ménétrier's disease [119,120]. TGFα suppresses gastric acidity, stimulates gastric epithelial
cell proliferation and induces gastric mucus production, all of which are characteristic features
of Ménétrier's disease. Transgenic mice that overexpress TGFα exhibit many features of
Ménétrier's disease including enlarged gastric folds, foveolar hyperplasia and reduced numbers
of chief cells and parietal cells with hypochlorhydria [121]. Patients diagnosed with Ménétrier's
disease exhibit increased immunoreactivity for TGFα [122]. To date, a systematic analysis of
other EGFR ligands has not been performed in this disease nor has there been a report of
targeted overexpression of any of the other EGFR ligands in the mouse stomach.
Perhaps the strongest evidence for the role of EGFR signaling in the pathogenesis of Ménétrier's
disease comes from pharmacologic blockade of EGFR in the treatment of patients with this
disease. We now have experience in treating eight patients with Ménétrier's disease with
cetuximab, a monoclonal antibody that inhibits the activity of the EGFR. All of the patients
treated thus far as part of an FDA-approved clinical trial with four weekly doses of cetuximab
have demonstrated clinical improvement in their predominant symptom. They also have
exhibited biochemical evidence of significant improvement in a number of parameters that
include decreased gastric wall thickness by CT scan, reduced proliferation in the involved
stomach (as determined by reduced active phosphorylated MAP kinase) and increased parietal
cell mass with decreased gastric pH (WH Fiske and RJ Coffey, unpublished observation). As
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assessed by electron microscopy, the integrity of tight junctions in the gastric mucosa of a
patient with Ménétrier's disease was improved after treatment with cetuximab [123].
In adolescents, there is an abrupt onset, spontaneously reversible form of Ménétrier's disease
that has been linked epidemiologically to CMV infection (see Gut Microbes and EGFR
section). We recently encountered a patient with acute onset, clinically and histologically
documented Ménétrier's disease whose signs and symptoms resolved in the two-month interval
from diagnosis to evaluation for entry into the cetuximab trial. We identified CMV nuclear
inclusions in his gastric epithelial cells and acute and convalescent serum titers for CMV
confirmed the diagnosis (WH Fiske and RJ Coffey, unpublished observation). Thus, CMV-
induced Ménétrier's disease can occur in immuno-competent adults. We now exclude patients
from our Ménétrier's disease trial if they have evidence of active H. pylori or CMV infection.
ErbB family members also play a role in gastric carcinogenesis. Some of these effects are
mediated through infection with H. pylori and are discussed in the section on Gut microbes
and EGFR. However, there is also evidence that ErbB family members play a more direct role
in gastric carcinogenesis as well.
Immunoreactive EGF is present in approximately 26% of gastric cancers, and the presence of
EGF in gastric cancer is associated with a greater degree of gastric wall invasion and lymph
node metastasis; the 5-year survival is worse for patients with EGF-positive tumors [124].
EGFR has also been identified in a small subset of gastric cancers, although this is uncommon.
In one study, high levels of EGFR immunoreactivity (2+ or 3+ by immunohistochemical
staining) were present in 9 of 413 tumor samples (2.2%), and low level expression (1+ staining)
was present in 8.2% of samples tested [125]. In tumors that demonstrated high levels of
expression by immunohistochemistry, FISH almost always demonstrated evidence of gene
amplification as the mechanism for overexpression [125]. Inhibition of EGFR signaling does
appear to be effective in reducing the growth of human gastric cancer cells both in vitro and
in vivo [126]. However, data evaluating the clinical efficacy of pharmacological blockade of
EGFR are lacking. There has been one uncontrolled Phase II clinical trial evaluating cetuximab
in combination with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal
junction (GEJ) adenocarcinoma [127]. This regimen appeared to be active in gastric cancer
with an acceptable rate of toxicity. Further randomized clinical trials evaluating cetuximab in
gastric cancer will need to be completed in order to assess its effectiveness.
ErbB2 has been shown to be overexpressed in human gastric carcinomas approximately 8–
14% of the time [128–130] and is associated with a worse prognosis [130–133]. Overexpression
of ErbB2 by immunohistochemistry is associated with greater depth of invasion, intestinal-
type carcinoma (not diffuse or mixed/anaplastic growth pattern), the presence of liver
metastases and more advanced stage [128,133]. Trastuzumab, a monoclonal antibody against
ErbB2, has been studied in both in vitro and in vivo models of gastric cancer. Trastuzumab
inhibited the growth of ErbB2-overexpressing SNU-216 cells. Phosphorylation of ErbB2 and
its downstream targets STAT3, AKT and ERK were also inhibited. This effect was synergistic
with cisplatin, and an additive effect was seen with trastuzumab plus 5-FU or trastuzumab plus
oxaliplatin [134]. In nude mouse xenografts, trastuzumab significantly suppressed the growth
of NCI-N87 cells [135]. The combination of trastuzumab with other chemotherapeutic agents
appears to be more effective than anti-cancer agents alone in xenograft models [136]. There
are anecdotal reports of the efficacy of trastuzumab in individuals with gastric carcinoma
[137,138], although large scale clinical trials are lacking.
ErbB3 may play a role in the progression to more dedifferentiated gastric cancers. NUGC-4
cells, derived from a signet ring carcinoma of the stomach, have a constitutively phosphorylated
ErbB3 that binds to phosphatidylinositol 3-kinase (PI3-kinase), although similarly derived
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HSC60 cells do not demonstrate phosphorylated ErbB3 or an association of ErbB3 with PI3-
kinase [139]. In contrast, phosphorylated ErbB3 is not detected in more differentiated cancer
cell lines such as SCH, MKN28, MKN74 and HSC57, although total ErbB3 can be detected.
ErbB4 may play a role in gastric carcinogenesis, although its role is not clear. In one study,
ErbB4 was not found to be expressed at the mRNA level in normal gastric mucosa. However,
it was expressed in 4 of 6 gastric cancers evaluated [111]. This same study performed
immunohistochemical analysis as well. In the normal stomach, immunostaining for ErbB4 was
detected in surface epithelial cells but not gastric fundic or pyloric glandular cells. ErbB4
staining was identified in all gastric cancers evaluated and appeared to be most intense in signet
ring cancers [111]. Mutations of ErbB4 in gastric cancer are rare. In a panel of 180 human
gastric cancers, mutations were found in only 1.7% of cases [140].
Intestine and colorectum
We have employed a genetic approach to identify a role for EGFR signaling in a post-initiation,
early stage of intestinal neoplasia. ApcMin (multiple intestinal neoplasia) mice are heterozygous for
an ENU-induced mutation in the Apc gene and develop multiple polyps in the small intestine,
and occasionally colon, at 3 months of age. Egfr null mice exhibit embryonic and/or perinatal
lethality on most genetic backgrounds, but wa2 mice harbor a spontaneous mutation in the
tyrosine kinase domain that produces a hypomorphic allele of Egfr. As mentioned above,
wa2 mice exhibit a 90% reduction in EGFR tyrosine kinase activity but are viable and fertile.
We crossed wa2 mutant mice to ApcMin mice and evaluated tumor multiplicity at 1 and 3 months
of age [141]. We were able to demonstrate that EGFR does not have a role in tumor initiation
(at 1 month there were just as many initiated events as determined by the number of
microadenomas and crypts containing cells with nuclear β-catenin). There was, however, a
90% reduction in the number of macroadenomas at 3 months of age. Thus, EGFR signaling
plays a critical role in the advancement from micro to macroadenomas in what we refer to as
the establishment phase of intestinal tumorigenesis. The few polyps that do form on a wa2
background are equivalently-sized to ApcMin polyps arising in Egfr wild-type mice and expand
in an EGFR-independent manner over a 9 month follow-up as determined by size and by
histology in a small cohort of mice by linear regression analysis. Fichera et al. also have
observed that EGFR signaling is required for early colonic tumor formation in mice treated
with the carcinogen azoxymethane [142]. The precise mechanism by which EGFR signaling
contributes to tumor establishment is not known but is believed to be through reduced
proliferation based upon results of Fichera et al. Treatment of established human colonic tumors
in nude mouse xenografts (HCA-7 and HCT-116) with a small molecule irreversible inhibitor
of EGFR signaling, EKB-569, resulted in concentration-dependent tumor growth inhibition,
revealing a role for EGFR signaling during later stages of tumorigenesis.
In addition to a Ménétrier's disease-like phenotype, MT-TGFα mice develop hyperplasia in
the small intestine and colon. Bill Dove et al. recently observed increased tumor multiplicity
in the jejunum of MT-TGFα transgenic mice crossed to ApcMin mice. There was no increase
in the size or net growth of established tumors, supporting a role for TGFα, like EGFR, in the
establishment phase of intestinal neoplasia. Interestingly, MT-TGFα mice exhibited 4-fold less
apoptosis in the jejunum than non-transgenic mice. However, the effects of the TGFα transgene
on tumor multiplicity in ApcMin mice were region-specific in that no effects on tumor number
were observed in the remainder of the small intestine or colon. We are not aware of other
transgenic mice overexpressing EGFR ligands that have been crossed to ApcMin mice.
Conversely, epiregulin null mice are the only EGFR ligand-deficient mice that have been
crossed to ApcMin mice; homozygous epiregulin null mice showed a dose-dependent trend
toward reduced tumor multiplicity, but it was not statistically significant [82].
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There is ample preclinical evidence for EGFR contributing to various aspects of colorectal
neoplasia. Fidler et al. have proposed that the EGFR in tumor-associated endothelial cells may
be the target of the EGFR tyrosine kinase inhibitor [143,144]. EGFR amplification and
mutations in the EGFR tyrosine kinase domain occur rarely in colorectal cancer [197]. The
frequency of the VIII EGFR variant in colorectal cancer is uncertain; two groups report widely
variant results [145,146]. These differences may be methodologic in nature; using a newly
developed, more sensitive, one-step PCR reaction, Dr. Albert Wong has observed the VIII
transcript in 9/16 colorectal tumors [147] (Albert Wong, personal communication).
The EGFR-targeting immunoglobulin IgG1 monoclonal antibody, cetuximab, and the IgG2
monoclonal antibody, panitumumab, are both approved in patients with metastatic CRC.
Cetuximab has been shown to be active as a single agent as well as in combination with
irinotecan in patients with chemorefractory metastatic CRC [148]. The activity of cetuximab
in combination with irinotecan- and oxaliplatin-based therapy in the first-line setting has been
demonstrated in phase II studies and a phase III study [149,150]. Panitumumab has been shown
to be active as single agent in chemorefractory metastatic CRC [151].
However, since only approximately 10% of patients respond to monotherapy, intense efforts
have been devoted to identification of biomarkers that predict responsiveness or non-
responsiveness to these EGFR-neutralizing monoclonal antibodies. Levels of total and
phosphorylated EGFR have not proven to be reliable predictors of responsiveness, findings
that may reflect the imprecision of the tools available. Conversely, retrospective [152–155]
and prospective [156] studies have identified mutant KRAS in CRC as a powerful predictor
of non-responsiveness to EGFR mAbs. Wild-type KRAS in CRC appears to be required for
responsiveness, although only a small proportion of patients will respond even when this is
present [153,157]. High levels of amphiregulin and epiregulin mRNA expression in the tumor
also predict responsiveness to cetuximab [156]. It appears that patients with mutant KRAS
tumors do not exhibit upregulation of amphiregulin or epiregulin; however, only a subset of
wild-type KRAS tumors exhibit upregulation of these EGFR ligands [158]. High amphiregulin
and epiregulin expression with wild-type KRAS primary CRCs correlates with response and
survival benefit after treatment with cetuximab and irinotecan for metastatic disease [158].
Mechanism(s) underlying these observations are unclear. Amongst other possibilities, the
sensitivity of these EGFR ligand-overexpressing tumors may reflect “growth factor addiction”
by the tumor. It is unclear whether cetuximab resistance is conferred by mutant KRAS itself
or by the company it keeps. If due directly to mutant KRAS, it may reflect that RAS is
downstream of EGFR, despite preclinical evidence that mutant RAS upregulates EGFR ligands
[159].
Using a battery of human colorectal cancer cell lines, Mariadason et al. recently reported that
simultaneous activation of RAS and PIK3CA pathways confer maximal resistance to
cetuximab. These investigators found that some CRC cell lines with mutant KRAS did respond
to cetuximab, a result that is at odds with the preponderance of the clinical data. Other
preclinical studies suggest that strategies that target Src [160] and HIF-1α [161] may work in
concert with cetuximab; in the latter case, siRNA knockdown of HIF-1α was able to restore
sensitivity to cetuximab in mutant RAS-transfected A431 cells.
In contrast to cetuximab, the reversible EGFR tyrosine kinase inhibitor gefitinib has little, if
any, activity in patients with advanced colorectal cancer [162]. Nevertheless, Baselaga et al.
have reported a response to combined iressa and cetuximab in 9/14 individuals with advanced
CRC (J. Baselga, personal communication). In addition, in vitro, combined pharmacological
blockade of TACE/ADAM-17, ligand uptake and EGFR tyrosine kinase activity resulted in
cooperative growth inhibition in HCA-7 cells [17].
Fiske et al. Page 13













The role of ErbB2 (HER-2/neu) in CRC is less clear than for EGFR. In 1997, Kapitanovi et
al. performed an immunohistochemical analysis of normal colon, hyperplastic polyps, tubular
adenomas, tubulovillous adenomas and adenocarcinomas and observed that these tissues
differed in their expression of ErbB2 [163]. Only 14% of normal colons exhibited moderate
or strong immunostaining for ErbB2 in contrast to 31% of hyperplastic polyps, 65% of tubular
adenomas, 100% of tubulovillous adenomas and 84% of adenocarcinomas. Furthermore, the
intensity of staining among adenocarcinomas correlated with Dukes’ stage at diagnosis,
metastasis-free survival and post-operative survival. Among tumors initially classified as
Dukes’ stage A or B which also demonstrated moderate or strong staining for ErbB2, 76%
developed distant metastases during follow-up, and these patients had significantly shorter
survival than those with weak staining for ErbB2. In another study, tumors from patients with
lymph node metastasis were more likely to exhibit ErbB2 immunostaining than those tumors
with no lymph node involvement [164].
Trastuzumab, a monoclonal antibody with activity against ErbB2, has been studied in both in
vitro and in vivo models of CRC [165]. Growth of heregrulin-1-stimulated HCA-7 cells was
inhibited by both celecoxib and trastuzumab. However, the combination appeared to be more
effective than either drug given alone. In Matrigel, trastuzumab alone had little effect on colony
number or size, whereas colony size was significantly reduced by the combination of
trastuzumab and celecoxib compared to celecoxib alone. Trastuzumab also inhibited the
growth of HCA-7 xenografts in nude mice. Again, this effect was more pronounced when used
in combination with celecoxib.
However, this high rate of ErbB2 expression has not been observed in other studies. In one
Phase II clinical trial, only 8% of patients screened for HER2/neu by immunohistochemistry
had overexpression demonstrated by moderate or strong staining. Partial responses to treatment
with trastuzumab were seen in 5 of 7 evaluable patients, but this study was stopped early due
to slow accrual [166]. As a result, there are no large randomized clinical trials evaluating the
effectiveness of trastuzumab in the treatment of patients with ErbB2-overexpressing CRCs.
Unlike in the case of breast cancer, the utility of using HER-2 overexpression to predict
response to HER-2 inhibition in colorectal cancer has been called into question. It has been
observed that the ability of the HER-2 monoclonal antibody 4D5 to inhibit cancer cell
proliferation and survival in vitro, or tumorigenicity in vivo, varies by cell line. For example,
4D5 inhibits proliferation in Caco-2 and HCA-7 but not DLD-1 or HT29 cells. Importantly,
the relative steady-state expression of HER-2 by immunohistochemistry failed to predict the
susceptibility of cancer cell lines to HER-2 inhibition. This may indicate that other methods
are needed to predict which patients may be likely to benefit from HER-2 inhibition [167].
Recently, Threadgill et al. have reported that targeted homozygous deletion of Erbb3 in the
mouse intestine using villin-Cre mice in combination with floxed Erbb3 results in a more
dramatic reduction in tumor burden than homozygous wa2 mice crossed to ApcMin mice [90].
Although there was a 90% reduction in tumor multiplicity in both strains, the intestinal tumors
were much smaller in ErbB3 ApcMin mice, and no colonic tumors developed. There was
reduced PI3-K/AKT signaling in the tumors with increased caspase3-mediated apoptosis. Loss
of ErbB3 in the intestinal epithelium has a much more pronounced antitumor effect than loss
of EGFR suggesting that non-EGFR combinations contribute to the majority of tumors (Fig.
3).
The role of ErbB4 (HER4) in CRC has not been as well studied as other receptors. In a
retrospective immunohistochemical review of 106 colorectal cancers, ErbB4 was expressed at
the membrane in 18.9% and in the cytoplasm in 28.3%. Tumors staining positive for ErbB4
were associated with lymph node involvement, although overall outcomes did not differ
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[168]. Mutations in ErbB4 can occur in CRC but are rare, happening in approximately 2.9%
of cases. All of those detected in one study by Soung et al. were missense mutations [140].
Interestingly, a germline polymorphism in the 5′ promoter region of ErbB4 (−782 G>T) has
been associated with increased risk of CRC (as well as breast cancer). In this study, the G allele
showed higher protein binding affinity than the T allele in competition experiments, and the T
allele had a more than 2.5-fold decrease in in vitro promoter activity as assessed by reporter
gene assays using MDA134 and MDA157 cells for transfection. Taken together, these findings
suggest that differences in these observed polymorphisms have implications on ErbB4
promoter activity and may lead to the observed association with CRC [169].
Areas of opportunity
Ligand delivery/unpeeling the onion
An understudied area is the cell surface trafficking of EGFR ligands in polarized epithelial
cells. This is likely to be physiologically relevant based on the recent observation that isolated
recessive renal hypomagnesemia is due to a mutation in the cytoplasmic tail of pro-EGF that
disrupts basolateral sorting of pro-EGF [170]. This leads to insufficient stimulation of
basolateral EGFRs in the proximal tubule of the kidney, resulting in impaired activation of the
Mg2+ channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6)
and magnesium wasting in the kidney. We have studied trafficking of EGF, TGFα and
amphiregulin in polarized MDCK cells and TGFα and amphiregulin in polarizing colorectal
cancer cell lines (reviewed in reference [2]).
The studies with TGFα are the most advanced. We have found that Naked2 acts as a cargo
recognition and targeting (CaRT) protein for basolateral delivery of TGFα [171,172]. Naked2
is a member of the Naked family (Naked Cuticle in Drosophila and vertebrate Naked1 and -2)
whose members act as antagonists of canonical Wnt signaling. Naked2 recognizes basolateral
sorting motifs in the cytoplasmic tail of Golgi-processed TGFα, coats TGFα-containing
exocytic vesicles and directs these vesicles to the basolateral corner of polarized epithelial cells
where the vesicles dock and fuse in a myristoylation-dependent manner (Fig. 4A). In
myristoylation-deficient G2ANaked2-expressing MDCK cells, these vesicles are directed to
the basolateral surface but are unable to fuse at the basolateral surface, leaving these vesicles
(and TGFα) trapped in the cytoplasm. Amphiregulin, however, is delivered properly to the
basolateral surface in these Naked2 mutant cells, suggesting that it uses a different basolateral
sorting machinery. We have exploited the trapped nature of these vesicles to biochemically
enrich and flow sort G2ANaked2-EGFP vesicles from MDCK cells. By LC/LC–MS/MS, we
have identified 389 proteins associated with this subset of basolaterally targeted vesicles
[173], thus setting the stage for rapid advances in this field.
Moreover, we have found that TGFα upregulates Naked2 in an EGFR-independent manner
[174]. Naked2 is a short-lived protein with a half-life of 1 h due to constitutive ubiquitin-
mediated proteasomal degradation by AO7, a ring finger E3 ligase (Fig. 4B). However, upon
interacting with the cytoplasmic tail of TGFα, Naked2 is protected from degradation. Thus,
TGFα ensures its proper delivery to the basolateral surface of polarized epithelial cells by
stabilizing its CaRT Naked2. Recent work indicates that expression of Naked2, in contrast to
Naked1 [175], is markedly reduced in over 60% of CRCs compared to adjacent normal colon
(RJ Coffey and W Ding unpublished observation). However, Naked2 levels are maintained in
adenomas, a finding that indicates loss of Naked2 is a late event in CRC.
Distinct biological roles among the EGFR ligands
Ebner and Derynck first reported that EGF and TGFα exhibit clear differences in disposition
upon ligand-receptor internalization [176]. Others have reported that the individual EGFR
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ligand determines the specificity of downstream signaling [27,177,178]. We have shown that
AR, but not TGFα, causes an EMT-like phenotype when added to MDCK cells [179,180].
Amphiregulin null mice, but not TGFα null mice, develop gastric cancer [181]. The judicious
use of overexpression and knockdown strategies of ERBB receptors and cognate ligands in
vitro and in vivo should help to elucidate distinct roles for the different ligands.
Stromal epithelial interactions
It will be informative to examine the relative contribution among ERBBs and their ligands in
stromal epithelial crosstalk in the gastrointestinal tract during development and in maintenance
of homeostasis in the adult [182]. It is instructive that stromal EGFR is critical for mammary
gland development [183].
Conclusion
The true physiological role of this family of receptors and their cognate ligands will come from
understanding their actions in vivo. Reductionist approaches in vitro will continue to be useful,
but attempts to use 3D models and reconstitution experiments combining different tissue
components (epithelial cells, pericryptal fibroblasts and other tissue elements) will be used
increasingly to better simulate in vivo conditions.
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Depiction of ERBBs and their cognate ligands. See text for details. AR, amphiregulin; BTC,
betacellulin; EPR, epiregulin.
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Simplified schema depicting effect of EGFR signaling on overall chloride secretion. Except
for CFTR, it is not intended to represent specific chloride or sodium transporters. Panels A and
B summarize studies performed in polarized T84 cells. (A) Left panel, carbachol (CCh) binds
and activates basolateral GPCR M3 muscarinic receptors that stimulate rapid, yet transient,
calcium-dependent apical chloride secretion. CCh activation of M3 receptors also triggers
ectodomain cleavage of proTGFα by TACE. The soluble ligand is avidly captured by
basolateral EGFRs; this transmits an incompletely understood signal that dampens chloride
secretion. Right panel, upon CCh stimulation, there is TACE-mediated rapid ectodomain
cleavage of TGFα and the soluble ligand is avidly captured by basolateral EGFRs (adapted
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from Fig. 7 in reference [29]). (B) In contrast to calcium-mediated chloride secretion, increased
intracellular cAMP (achieved e.g. by PAR-2, VIP, dibutryl cAMP, forskolin) stimulates slower
onset, more sustained chloride secretion by a PKA-mediated direct effect on the CFTR chloride
channel. Depicted here is activation of basolateral PAR-2 that results in Src-dependent
transactivation of the EGFR. In this instance, there appears to be ligand-independent EGFR
activation that contributes to chloride secretion. (C) In normal mouse colon, addition of EGF
inhibits cAMP-dependent ion transport; however, in the setting of inflammation, EGF
stimulates sodium reabsorption. In the inflamed mouse colon, this effect is blunted by
tetrodotoxin, indicating that the effect is mediated, at least in part, through neurons.Ⓟ indicates
activated, tyrosine phosphorylated EGFR.
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Receptor combinations contributing to CRC growth. Results from inhibiting EGFR or
conditional deletion of ErbB3 is consistent with a model whereby EGFR-containing dimers
contribute to proliferation, while ErbB3 dimers largely contribute to survival. CRC growth
requires both signals. When EGFR is blocked, tumors have reduced proliferation. However,
tumors that lack EGFR have normal growth rates, presumably using other ErbB signals. When
ErbB3 is lost, both a proliferation and survival signal are lost, resulting in a dramatic reduction
in tumorigenesis.
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Model for TGFα-induced Naked2 stabilization. (A) Naked2 acts as a CaRT to escort TGFα-
containing vesicles to the basolateral corner of polarized epithelial cells where they dock and
fuse in Naked2 myristoylation-dependent manner. (B) In the absence of TGFα, Naked2 is
ubiquitylated by AO7 and undergoes rapid proteasomal degradation. When TGFα binds
Naked2, there is decreased binding of AO7 to Naked2 and Naked2 is protected from
degradation. This action of TGFα is EGFR-independent. Figure is adapted from reference
[172].
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